Pfizer may be the first company to introduce a "superpill," one that combines its hypertension drug Norvasc and its cholesterol-lowering agent Lipitor. Merck will follow with a combination of Zocol and Zetia, while Bristol-Myers Squibb is developing a single-pill version of aspirin and Pravachol, its statin drug. These superpills could result in significant declines in heart disease, British researchers say.

Related Summaries